{"schema_version":"secwatch.filing_event.v1","accession":"0001641489-23-000046","form_type":"8-K","ticker":"VTVT","cik":"0001641489","company_name":"vTv Therapeutics Inc.","filed_at":"2023-07-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.653212+00:00","generated_at":"2026-06-13T05:37:23.484728+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"vTv Therapeutics gets Nasdaq extension to Dec 2023; must reverse split by Nov 22","bullets":["Nasdaq extended bid price compliance deadline to December 18, 2023.","Company must effect reverse stock split (1:10 to 1:20) by November 22, 2023.","Stockholder approval for reverse split required by October 30, 2023.","No assurance reverse split will ensure compliance; stock price impact uncertain."],"urls":{"canonical":"https://secwatch.observer/filing/0001641489-23-000046","json":"https://secwatch.observer/filing/0001641489-23-000046.json","markdown":"https://secwatch.observer/filing/0001641489-23-000046.md","text":"https://secwatch.observer/filing/0001641489-23-000046.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1641489/000164148923000046/0001641489-23-000046-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1641489/000164148923000046/vtvt-20230717.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T05:37:23.484728+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5bdf6170b211f9b20680985349b89a893bf5b194","claim":"vTv Therapeutics Inc. received a nasdaq extension granted notice regarding minimum bid price.","evidence_excerpt":"July 17, 2023, the Company received notice from Nasdaq that, based upon the completed questionnaire and the expedited review process, it had approved the Company’s request to extend the period for the Company to regain compliance with the Minimum Bid Requirement until December 18, 2023. Nasdaq noted that the extension was based upon the Company’s representation that it would complete a reverse stock split no later than November 22, 2023, at a ratio between 1:10 and 1:20, and that it would obtain stockholder approval for such a reverse stock split on or before October 30, 2023. There can be no","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1641489/000164148923000046/0001641489-23-000046-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"extension granted"},{"label":"Deficiency","value":"minimum bid price"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}